Loading company…
Stablix develops targeted protein stabilization medicines for conditions with unmet medical needs.
Founded in 2021 and based in New York, US, Stablix is developing small molecules that recruit deubiquitinase enzymes to stabilize target proteins. Its RESTORED™ platform originated in a Columbia University laboratory and is intended for oncology, immunology, and rare diseases. The company raised USD 63 million in Series A funding in June 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in